An2 Therapeutics Stock Three Year Return
| ANTX Stock | USD 1.37 0.02 1.44% |
AN2 Therapeutics fundamentals help investors to digest information that contributes to AN2 Therapeutics' financial success or failures. It also enables traders to predict the movement of AN2 Stock. The fundamental analysis module provides a way to measure AN2 Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AN2 Therapeutics stock.
AN2 | Three Year Return |
AN2 Therapeutics Company Three Year Return Analysis
AN2 Therapeutics' Tree Year Return shows the total annualized return generated from holding a fund or ETFs for the last three years. The return measure includes capital appreciation, losses, dividends paid, and all capital gains distributions. This return indicator is considered by many investors to be solid measures of fund mid-term performance.
More About Three Year Return | All Equity Analysis
Three Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
AN2 Three Year Return Driver Correlations
Understanding the fundamental principles of building solid financial models for AN2 Therapeutics is extremely important. It helps to project a fair market value of AN2 Stock properly, considering its historical fundamentals such as Three Year Return. Since AN2 Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of AN2 Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of AN2 Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Although Three Year Fund Return indicator can give a sense of overall fund mid-term potential, it is recommended to compare fund performances against other similar funds, ETFs, or market benchmarks for the same 3 year interval.
| Competition |
AN2 Return On Tangible Assets
Return On Tangible Assets |
|
Based on the latest financial disclosure, AN2 Therapeutics has a Three Year Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
AN2 Three Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AN2 Therapeutics' direct or indirect competition against its Three Year Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AN2 Therapeutics could also be used in its relative valuation, which is a method of valuing AN2 Therapeutics by comparing valuation metrics of similar companies.AN2 Therapeutics is currently under evaluation in three year return category among its peers.
AN2 Fundamentals
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.43 | ||||
| Current Valuation | (53.71 M) | ||||
| Shares Outstanding | 29.88 M | ||||
| Shares Owned By Insiders | 21.63 % | ||||
| Shares Owned By Institutions | 52.31 % | ||||
| Number Of Shares Shorted | 133.57 K | ||||
| Price To Earning | 3.96 X | ||||
| Price To Book | 0.47 X | ||||
| EBITDA | 4.9 M | ||||
| Net Income | (64.73 M) | ||||
| Cash And Equivalents | 113.39 M | ||||
| Cash Per Share | 5.84 X | ||||
| Total Debt | 14.04 M | ||||
| Current Ratio | 28.17 X | ||||
| Book Value Per Share | 4.19 X | ||||
| Cash Flow From Operations | (53.29 M) | ||||
| Short Ratio | 0.82 X | ||||
| Earnings Per Share | (1.99) X | ||||
| Target Price | 2.67 | ||||
| Number Of Employees | 41 | ||||
| Beta | -0.22 | ||||
| Market Capitalization | 41.53 M | ||||
| Total Asset | 138.74 M | ||||
| Retained Earnings | (154.46 M) | ||||
| Working Capital | 96.46 M | ||||
| Net Asset | 138.74 M |
About AN2 Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AN2 Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AN2 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AN2 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for AN2 Stock Analysis
When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.